Beyond immune rejection: integrative genetic engineering strategies for overcoming coagulopathy in xenotransplantation.
Abstract
The four-decade evolution of genetically engineered (GE) pigs from the first α-1,3-galactosyltransferase knockout in 2003 to today's 10-gene and 69-edit donors has progressively dismantled the immunologic barriers to xenotransplantation. Hyperacute and acute humoral rejection have been largely overcome through triple knockout of xenoreactive carbohydrate antigens and transgenic expression of human complement regulators. Yet a less appreciated barrier now dominates long-term graft survival: pig-to-human coagulation dysregulation. Molecular incompatibility between porcine endothelial regulators of hemostasis, particularly thrombomodulin, endothelial protein C receptor, and the CD39 axis, and the primate coagulation cascade drives thrombotic microangiopathy and consumptive coagulopathy that erode graft function after immunologic control is achieved. The six reported human cases (Cases 1-6, numbered chronologically) confirm this transition. Notably, the 10-gene configuration now used in most clinical xenotransplants reflects the proprietary design of a single industrial source, not a biologically derived optimum. This review traces the historical development of GE pigs, synthesizes the rationale for integrative endothelial humanization, and argues that scientific progress requires diverse new gene combinations and, ultimately, organ-tailored donor pigs.
